Leerink Partnrs downgraded shares of CureVac (NASDAQ:CVAC – Free Report) from an outperform rating to a market perform rating in a research note published on Thursday, Zacks.com reports.
CVAC has been the subject of a number of other research reports. Guggenheim reiterated a neutral rating on shares of CureVac in a report on Friday, April 5th. SVB Leerink downgraded CureVac from an outperform rating to a market perform rating and lowered their price target for the stock from $12.00 to $4.00 in a report on Thursday. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of Hold and an average target price of $8.33.
View Our Latest Analysis on CVAC
CureVac Trading Up 0.9 %
Institutional Investors Weigh In On CureVac
Several large investors have recently modified their holdings of the business. Ballentine Partners LLC bought a new stake in shares of CureVac in the first quarter worth $38,000. China Universal Asset Management Co. Ltd. lifted its position in shares of CureVac by 95.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,738 shares of the company’s stock worth $39,000 after purchasing an additional 2,804 shares in the last quarter. Vontobel Holding Ltd. bought a new stake in shares of CureVac in the fourth quarter worth $45,000. Optiver Holding B.V. lifted its position in shares of CureVac by 2,407.0% in the third quarter. Optiver Holding B.V. now owns 6,844 shares of the company’s stock worth $47,000 after purchasing an additional 6,571 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in shares of CureVac in the fourth quarter worth $68,000. 17.26% of the stock is currently owned by institutional investors.
CureVac Company Profile
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza.
Further Reading
- Five stocks we like better than CureVac
- Insider Trading – What You Need to Know
- Snap Crackles and Pops on Surprise Profit and Raised Guidance
- 3 Healthcare Dividend Stocks to Buy
- MarketBeat Week in Review – 4/22 – 4/26
- How to invest in blue chip stocks
- 3 Stocks Leading the U.S. Agriculture Comeback
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.